Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation

References

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):1–8. doi:10.3322/caac.21208.
   PubMed Web of Science ®Google Scholar
• Niederhuber JE, Brennan MF, Menck HR. The national cancer data base report on pancreatic cancer. Cancer. 1995;76(9):1671–1677. doi:10.1002/1097-0142(19951101)76:9<1671::aid-cncr2820760926>3.0.co;2-r.
   PubMed Web of Science ®Google Scholar
• Pezzilli R, Serra C, Ricci C, Casadei R, Monari F, D’Ambra M, Minni F. Radiofrequency ablation for advanced ductal pancreatic carcinoma: is this approach beneficial for our patients? A systematic review. Pancreas. 2011;40(1):163–165. doi:10.1097/MPA.0b013e3181eab751.
   PubMed Web of Science ®Google Scholar
• Scheffer HJ, Nielsen K, de Jong MC, van Tilborg AAJM, Vieveen JM, Bouwman A, Meijer S, van Kuijk C, van Den Tol PMP, Meijerink MR. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interventional Radiol. 2014;25(7):997–1011. doi:10.1016/j.jvir.2014.01.028.
   PubMed Web of Science ®Google Scholar
• Rubinsky B, Onik G, Mikus P. irreversible electroporation: a new ablation modality — clinical implications. Technol Cancer Res Treat. 2007;6(1):37–48. doi:10.1177/153303460700600106.
   PubMed Web of Science ®Google Scholar
• Paiella S, Butturini G, Frigerio I, Salvia R, Armatura G, Bacchion M, Fontana M, D’Onofrio M, Martone E, Bassi C. Safety and feasibility of Irreversible Electroporation (IRE) in patients with locally advanced pancreatic cancer: results of a prospective study. Dig Surg. 2015;32(2):90–97. doi:10.1159/000375323.
   PubMed Web of Science ®Google Scholar
• Martin RC 2nd, Kwon D, Chalikonda S, Sellers M, Kotz E, Scoggins C, McMasters KM, Watkins K. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg. 2015;262(3):486–494; discussion 92-4. doi:10.1097/SLA.0000000000001441.
   PubMed Web of Science ®Google Scholar
• Mansson C, Bergenfeldt M, Brahmstaedt R, Karlson BM, Nygren P, Nilsson A. Safety and preliminary efficacy of ultrasound-guided percutaneous irreversible electroporation for treatment of localized pancreatic cancer. Anticancer Res. 2014;34:289–293.
   PubMed Web of Science ®Google Scholar
• Scheffer HJ, Vroomen LG, de Jong MC, Melenhorst MC, Zonderhuis BM, Daams F, Vogel JA, Besselink MGH, van Kuijk C, Witvliet J, et al. Ablation of locally advanced pancreatic cancer with percutaneous irreversible electroporation: results of the phase I/II PANFIRE study. Radiology. 2017;282(2):585–597. doi:10.1148/radiol.2016152835.
   PubMed Web of Science ®Google Scholar
• Bulvik BE, Rozenblum N, Gourevich S, Ahmed M, Andriyanov AV, Galun E, Goldberg SN. Irreversible electroporation versus radiofrequency ablation: a comparison of local and systemic effects in a small-animal model. Radiology. 2016;280(2):413–424. doi:10.1148/radiol.2015151166.
   PubMed Web of Science ®Google Scholar
• Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, Solt S, Dorman A, Wamwea A, Yager A, et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res. 2014;2(7):616–631. doi:10.1158/2326-6066.CIR-14-0027.
   PubMed Web of Science ®Google Scholar
• Schnurr M, Duewell P, Bauer C, Rothenfusser S, Lauber K, Endres S, Kobold S. Strategies to relieve immunosuppression in pancreatic cancer. Immunotherapy. 2015;7(4):363–376. doi:10.2217/imt.15.9.
   PubMed Web of Science ®Google Scholar
• Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 2011;60(10):1419–1430. doi:10.1007/s00262-011-1028-0.
   PubMed Web of Science ®Google Scholar
• Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006;12(18):5423–5434. doi:10.1158/1078-0432.CCR-06-0369.
   PubMed Web of Science ®Google Scholar
• Koido S, Homma S, Okamoto M, Takakura K, Mori M, Yoshizaki S, Tsukinaga S, Odahara S, Koyama S, Imazu H, et al. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms’ tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer. Clin Cancer Res. 2014;20(16):4228–4239. doi:10.1158/1078-0432.CCR-14-0314.
   PubMed Web of Science ®Google Scholar
• Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, et al. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015;33(12):1325–1333. doi:10.1200/JCO.2014.57.4244.
   PubMed Web of Science ®Google Scholar
• Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA, Donehower RC, Jaffee EM, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother (hagerstown, Md: 1997). 2013;36(7):382–389. doi:10.1097/CJI.0b013e31829fb7a2.
   PubMed Web of Science ®Google Scholar
• Jose A, Sobrevals L, Ivorra A, Fillat C. Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models. Cancer Lett. 2012;317(1):16–23. doi:10.1016/j.canlet.2011.11.004.
   PubMed Web of Science ®Google Scholar
• Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30(6):899–911. doi:10.1016/j.immuni.2009.03.019.
   PubMed Web of Science ®Google Scholar
• Santegoets SJ, Dijkgraaf EM, Battaglia A, Beckhove P, Britten CM, Gallimore A, Godkin A, Gouttefangeas C, de Gruijl TD, Koenen HJPM, et al. Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol Immunother. 2015;64(10):1271–1286. doi:10.1007/s00262-015-1729-x.
   PubMed Web of Science ®Google Scholar
• Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016;22(4):433–438. doi:10.1038/nm.4051.
   PubMed Web of Science ®Google Scholar
• Clouthier DL, Ohashi PS. Costimulation, a surprising connection for immunotherapy. Science (New York, NY). 2017;355(6332):1373–1374. doi:10.1126/science.aan1467.
   Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–330. doi:10.1038/nature21349.
   PubMed Web of Science ®Google Scholar
• Bastianpillai C, Petrides N, Shah T, Guillaumier S, Ahmed HU, Arya M. Harnessing the immunomodulatory effect of thermal and non-thermal ablative therapies for cancer treatment. Tumour Biol. 2015;36(12):9137–9146. doi:10.1007/s13277-015-4126-3.
   PubMed Web of Science ®Google Scholar
• O’Brien MA, Power DG, Clover AJ, Bird B, Soden DM, Forde PF. Local tumour ablative therapies: opportunities for maximising immune engagement and activation. Biochim Biophys Acta. 2014;1846(2):510–523. doi:10.1016/j.bbcan.2014.09.005.
   PubMed Web of Science ®Google Scholar
• Dromi SA, Walsh MP, Herby S, Traughber B, Xie J, Sharma KV, Sekhar KP, Luk A, Liewehr DJ, Dreher MR, et al. Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity. Radiology. 2009;251(1):58–66. doi:10.1148/radiol.2511072175.
   PubMed Web of Science ®Google Scholar
• Neal RE 2nd, Rossmeisl JH Jr., Robertson JL, Arena CB, Davis EM, Singh RN, Stallings J, Davalos RV, Rubinsky B. Improved local and systemic anti-tumor efficacy for irreversible electroporation in immunocompetent versus immunodeficient mice. PLoS One. 2013;8(5):e64559. doi:10.1371/journal.pone.0064559.
   PubMed Web of Science ®Google Scholar
• Shao Q, O’Flanagan S, Lam T, Roy P, Pelaez F, Burbach BJ, Azarin SM, Shimizu Y, Bischof JC. Engineering T cell response to cancer antigens by choice of focal therapeutic conditions. Int J Hyperthermia. 2019;36(1):130–138. doi:10.1080/02656736.2018.1539253.
   PubMed Web of Science ®Google Scholar
• Pandit H, Hong YK, Li Y, Rostas J, Pulliam Z, Li SP, Martin RCG. Evaluating the regulatory immunomodulation effect of Irreversible Electroporation (IRE) in pancreatic adenocarcinoma. Ann Surg Oncol. 2019;26(3):800–806. doi:10.1245/s10434-018-07144-3.
   PubMed Web of Science ®Google Scholar
• Fietta AM, Morosini M, Passadore I, Cascina A, Draghi P, Dore R, Rossi S, Pozzi E, Meloni F. Systemic inflammatory response and downmodulation of peripheral CD25+Foxp3+ T-regulatory cells in patients undergoing radiofrequency thermal ablation for lung cancer. Hum Immunol. 2009;70(7):477–486. doi:10.1016/j.humimm.2009.03.012.
   PubMed Web of Science ®Google Scholar
• Oji Y, Nakamori S, Fujikawa M, Nakatsuka S-I, Yokota A, Tatsumi N, Abeno S, Ikeba A, Takashima S, Tsujie M, et al. Overexpression of the Wilms’ tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci. 2004;95(7):583–587. doi:10.1111/j.1349-7006.2004.tb02490.x.
   PubMed Web of Science ®Google Scholar
• Zhao J, Wen X, Tian L, Li T, Xu C, Wen X, Melancon MP, Gupta S, Shen B, Peng W, et al. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer. Nat Commun. 2019;10(1):899. doi:10.1038/s41467-019-08782-1.
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ (clinical Research Ed). 2007;335(7624):806–808. doi:10.1136/bmj.39335.541782.AD.
   PubMed Web of Science ®Google Scholar
• Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1727–1733. doi:10.1245/s10434-009-0408-6.
   PubMed Web of Science ®Google Scholar
• van Tilborg AA, Scheffer HJ, Nielsen K, van Waesberghe JH, Comans EF, van Kuijk C, van Den Tol PM, Meijerink MR. Transcatheter CT arterial portography and CT hepatic arteriography for liver tumor visualization during percutaneous ablation. J Vasc Interventional Radiol. 2014;25(7):1101–11.e4. doi:10.1016/j.jvir.2014.02.008.
   PubMed Web of Science ®Google Scholar
• Santegoets SJ, Stam AG, Lougheed SM, Gall H, Scholten PE, Reijm M, Jooss K, Sacks N, Hege K, Lowy I, et al. T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother. 2013;62(2):245–256. doi:10.1007/s00262-012-1330-5.
   PubMed Web of Science ®Google Scholar
• Molenkamp BG, Sluijter BJ, van Leeuwen PA, Santegoets SJ, Meijer S, Wijnands PG, Haanen JBAG, van Den Eertwegh AJM, Scheper RJ, de Gruijl TD. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin Cancer Res. 2008;14(14):4532–4542. doi:10.1158/1078-0432.CCR-07-4711.
   PubMed Web of Science ®Google Scholar
• Santegoets SJ, Stam AG, Lougheed SM, Gall H, Jooss K, Sacks N, Hege K, Lowy I, Scheper RJ, Gerritsen WR, et al. Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. J Immunother Cancer. 2014;2:31. doi:10.1186/s40425-014-0031-3.
   PubMedGoogle Scholar
• Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A. 2008;105(51):20410–20415. doi:10.1073/pnas.0810114105.
   PubMed Web of Science ®Google Scholar